P/E Ratio

The P/E ratio of 17.2x means that investors are currently paying $17.20 for every $1 of Catalyst Pharmaceuticals' trailing twelve months of earnings per share — a measure of how much the market is willing to pay for each dollar of profit.

This is well below the healthcare sector median of 24.6x, placing Catalyst in the 15th percentile among its sector peers, indicating it trades at a relatively low valuation compared to the typical healthcare company. Trend data for the P/E ratio is not available (N/A), with both the year-over-year and quarter-over-quarter changes reported as N/A, so no directional movement can be assessed. The combination of a below-median P/E and the absence of historical trend means the metric carries limited forward-looking information, but the low multiple by itself may reduce downside valuation risk if earnings remain stable. This metric supports the overall NEUTRAL verdict because the low valuation suggests limited downside, while the lack of trend data prevents any clear bullish or bearish signal.

Frequently Asked Questions

Closest Sector Peers